Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Regulatory Approval

Eikon Therapeutics Reports 31.3% Response Rate for EIK1003 in Phase 1/2 Oncology Trial

Eikon Therapeutics unveiled clinical data for three oncology candidates at the 2026 ESMO Congress, highlighted by a 31.3% response rate for its PARP1 inhibitor EIK1003 in certain patient populations. The data supports the continued development of selective PARP1 and WRN helicase inhibitors through 2027.

Chemistry-lab-experiment, chemistry-lab, research, chemistry. Stock photo illustrating Eikon Therapeutics' regulatory approval story.
Eikon Therapeutics, Inc. · Healthcare · Photo: 4339272 / Pixabay

Key highlights

  • EIK1003 monotherapy demonstrated a 31.3% objective response rate in PARP-naïve oncology patients
  • Initial Phase 1/2 data for CNS-penetrant EIK1004 showed minimal Grade 3 or higher hematologic toxicities
  • Pharmacokinetic data for WRN inhibitor EIK1005 supports a once-weekly administration schedule
  • Management confirmed a cash runway extending into the second half of 2027 with 531.2 million USD in assets
  • Combination studies for EIK1003 with paclitaxel and abiraterone showed safety consistent with established profiles

ESMO 2026 Presentation Details

Eikon Therapeutics presented a trio of clinical updates at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid. The presentation centered on the Phase 1/2 trial of EIK1003, a selective, non-brain-penetrant PARP1 inhibitor. Among 49 evaluable patients in the monotherapy cohort, the objective response rate (ORR) reached 31.3% in participants who had not previously received a PARP inhibitor. The study included patients with HRR-mutated breast, ovarian, prostate, and pancreatic cancers. Additionally, the company introduced initial safety and pharmacokinetic data for EIK1004, a CNS-penetrant PARP1 inhibitor, and EIK1005, its internally developed WRN helicase inhibitor.

Strategic Clinical Milestones

  • Selective PARP1 inhibition aims to reduce the hematological toxicities associated with dual PARP1/2 inhibitors
  • EIK1003 combination trials with abiraterone and paclitaxel showed safety profiles consistent with existing therapies
  • The CNS-penetrant candidate EIK1004 offers potential for treating tumors with brain metastases
  • EIK1005 represents the first clinical translation of Eikons proprietary discovery platform into WRN inhibition
  • Additional data readouts across the oncology portfolio are anticipated throughout 2027

Financial Position and Capitalization

Eikon Therapeutics maintains a substantial liquidity position to support its expanding clinical pipeline. As of August 2026, the company reported 531.2 million USD in liquid assets, providing an operational runway into the second half of 2027. This follows a period of significant capital formation, including a 381.0 million USD initial public offering in February 2026 and a 350.7 million USD Series D financing round in 2025. With a market capitalization of approximately 446.3 million USD, Eikon operates as a pre-revenue biotechnology firm, focusing its resources on the high-cost development phases of its DNA damage response and synthetic lethality programs.

Eikon Therapeutics, Inc. share price · last month
Line chart of Eikon Therapeutics, Inc.'s share price over the last month, from $7.70 on 19 Oct → $5.38 on 16 Nov; our story on 23 Oct at $8.24.

Down 34.6% since our story on 23 Oct: $8.24 when we broke it → $5.38 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$7.70
20 Oct$8.18
21 Oct$8.00
22 Oct$8.24
23 Oct$7.26
26 Oct$5.54
27 Oct$5.55
28 Oct$5.54
29 Oct$5.35
30 Oct$5.31
2 Nov$5.68
3 Nov$5.55
4 Nov$6.39
5 Nov$5.84
6 Nov$5.90
9 Nov$5.87
10 Nov$6.13
11 Nov$6.67
12 Nov$6.04
13 Nov$5.98
16 Nov$5.38

Oncology Sector Context

The PARP inhibitor landscape is currently undergoing a shift toward selectivity as researchers look to improve upon the safety profiles of established agents like olaparib and niraparib. By targeting PARP1 exclusively, developers hope to maintain antitumor efficacy while minimizing bone marrow suppression. Eikons expansion into WRN helicase inhibition further aligns with the industry trend toward synthetic lethality targets in oncology. The WRN helicase program, in particular, is being evaluated for potential synergy with checkpoint inhibitors such as pembrolizumab, reflecting a broader sector movement toward multi-mechanism combination regimens in refractory cancer settings where existing standard-of-care options are limited.

Earlier announcements by Eikon Therapeutics, Inc.
DateAnnouncementAmount
18 Oct 2026Publication of seven clinical abstracts for presentation at the ESMO Congress across the oncology pipelineSource: biospace.com–
15 Oct 2026Submission of Investigational New Drug (IND) application to the U.S. FDA for EIK1006 in prostate cancerSource: globenewswire.com–
13 Aug 2026Second quarter 2026 financial results report and oncology clinical pipeline updatesSource: SEC filing–
27 Jul 2026First patient dosed in TeLuRide-008 Phase 2/3 registrational trial of EIK1001 in non-small cell lung cancerSource: nasdaq.com–
04 Feb 2026Pricing of upsized initial public offering of 21,177,600 common shares at $18.00 per shareSource: eikontx.com$381.0 Million
26 Feb 2025Initial closing of Series D venture financing round to advance clinical-stage oncology programsSource: eikontx.com$350.7 Million

Management commentary

“These data strengthen the foundation of our clinical-stage pipeline, with encouraging evidence of activity and tolerability across our selective PARP1 programs.”

Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon
Eikon Therapeutics, Inc. · financial snapshot
Share price$8.24
Market cap$446M
1-month price change-8.24%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Eikon Therapeutics, Inc. announcing clinical trial data for EIK1003, EIK1004, and EIK1005.

Read the filing ↗

Track Eikon Therapeutics, Inc. live

Get the next Eikon Therapeutics, Inc. SEC filing seconds after it lands.

More in Approvals

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.